Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis

NCT07660835 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

DRUG: Nemolizumab

Sponsor

Galderma R&D